GynecologyGynecology2079-56962079-5831Consilium Medicum8023310.26442/20795696.2021.4.201097Research ArticleThe effectiveness of therapy for endometriosis-associated pelvic pain resistant to surgical treatmentOrazovMekan R.<p>D. Sci. (Med.), Prof.</p>omekan@mail.ruhttps://orcid.org/0000-0002-5342-8129RadzinskyViktor E.<p>Sci. (Med.), Prof., Acad. RAS</p>omekan@mail.ruOrekhovRoman E.<p>Assistant of Professor</p>romanorekhovv@ya.ruPeople’s Friendship University of Russia (RUDN University)220920212343143231609202116092021Copyright © 2021, Consilium Medicum2021<p><strong>Aim. </strong>To assess the efficacy and safety of 24-week therapy with dienogest in patients with endometriosis-associated pelvic pain resistant to surgical treatment.</p>
<p><strong>Materials and methods. </strong>The study included 126 patients aged 3340 years with external genital endometriosis (EGE) confirmed by laparoscopy and morphological examination (International classification of diseases, 10th revision [ICD-10] N80.1, 80.2, 80.3, 80.4) and with pelvic pain that occurred in 36 months after surgical treatment of EGE (ICD-10 N94.8 "Pain and other conditions associated with female genital organs and menstrual cycle"). The participants were stratified into 3 groups by pain syndrome severity according to the Verbal Analog Scale (VAS). The group-1 included patients with 1040 mm, the group-2 with 4170 mm, and the group-3 with more than 71 mm pain score according to VAS. Patients of all 3 groups were prescribed the denogest (Zafrilla, Gedeon Richter, 2 mg/day) for 24 weeks (according to the current pack insert). Follow-up and assessment of treatment outcomes were carried out over 6 months. Study design: prospective, observational, comparative study.</p>
<p><strong>Results. </strong>In 3 and 6 months after the start of therapy, there was a stable statistically significant decrease in pain syndrome severity by all scales (Biberoglu Behrman Scale, Numeral Rating Scale, VAS) in each of the groups (<em>p</em>0.01). In all 3 groups, treatment led to an improvement in sexual function, assessed with the Female Sexual Function Index scale, in 3 and 6 months after the start of therapy (<em>p</em>0.01). According to the quality of life in endometriosis (Endometriosis Health Profile) questionnaire, the analyzed indicators significantly improved in all study participants (<em>p</em>0.01).</p>
<p><strong>Conclusion. </strong>Dienogest is an effective and safe method for the treatment of endometriosis-associated pelvic pain resistant to surgical treatment. Treatment with dienogest for 24 weeks effectively relieves pain, improves symptoms, and improves quality of life and sexual functioning.</p>endometriosispelvic paindienogestquality of lifeэндометриозтазовая больдиеногесткачество жизни[Royal College of Obstetricians and Gynaecologists. Chronic Pelvic Pain, Initial Management (Green-top 41). Royal College of Obstetricians and Gynaecologists, 2012.][Vincent K, Evans E. An update on the management of chronic pelvic pain in women. Anaesthesia. 2021;76(Suppl.4):96-107. DOI:10.1111/anae.15421; PMID: 33682093][Steege JF, Siedhoff MT. Chronic pelvic pain. Obstet Gynecol. 2014;124(3):616-9.][Moore J, Kennedy S. Causes of chronic pelvic pain. Baillières Best Pract Res Clin Obstet Gynaecol. 2000;14(3):389-402.][Tirlapur SA, Kuhrt K, Chaliha C, et al. The ’evil twin syndrome’ in chronic pelvic pain: a systematic review of prevalence studies of bladder pain syndrome and endometriosis. Int J Surg. 2013;11:233-7.][Оразов М.Р., Радзинский В.Е., Михалева Л.М., и др. Диспареуния как визитная карточка инфильтративных форм эндометриоза. Трудный пациент. 2021;1 [Orazov MR, Radzinskii VE, Mikhaleva LM, et al. Dispareuniia kak vizitnaia kartochka infil'trativnykh form endometrioza. Trudnyi patsient. 2021;1 (in Russian)].][Guo SW. Recurrence of endometriosis and its control. Hum Reprod Update. 2009;15:441-61. DOI:10.1093/humupd/dmp007][Sinaii N, Plumb K, Cotton L, et al. Differences in characteristics among 1,000 women with endometriosis based on extent of disease. Fertil Steril. 2008;89:538-45.][Koninckx PR, Meuleman C, Demeyere S, et al. Suggestive evidence that pelvic endometriosis is a progressive disease, whereas deeply infiltrating endometriosis is associated with pelvic pain. Fertil Steril. 1991;55:759-65.][Burney RO, Giudice LC. Pathogenesis and pathophysiology of endometriosis. Fertil Steril. 2012;98:511-9.][Оразов М.Р., Радзинский В.Е., Хамошина М.Б., и др. Эффективность лечения тазовой боли, обусловленной наружным генитальным эндометриозом. Трудный пациент. 2017;8-9 [Orazov MR, Radzinskii VE, Khamoshina MB, et al. Effektivnost' lecheniia tazovoi boli, obuslovlennoi naruzhnym genital'nym endometriozom. Trudnyi patsient. 2017;8-9 (in Russian)].][Brown J, Crawford TJ, Allen C, et al. Nonsteroidal anti-inflammatory drugs for pain in women with endometriosis. Cochrane Database Syst Rev. 2017;1:CD004753.][Dunselman GA, Vermeulen N, Becker C, et al. ESHRE guideline: Management of women with endometriosis. Hum Reprod. 2014;29:400-12.][Brown J, Pan A, Hart RJ. Gonadotrophin-releasing hormone analogues for pain associated with endometriosis. Cochrane Database Syst Rev. 2010:CD008475.][Practice Committee of American Society for Reproductive Medicine. Treatment of pelvic pain associated with endometriosis. Fertil Steril. 2008;90:S260-9.][Brown J, Kives S, Akhtar M. Progestagens and antiprogestagens for pain associated with endometriosis. Cochrane Database Syst Rev. 2012:CD002122.][Grandi G, Mueller M, Bersinger NA, et al. Does dienogest influence the inflammatory response of endometriotic cells? A systematic review. Inflamm Res. 2016;65:183-92.][Harada T, Taniguchi F. Dienogest: A new therapeutic agent for the treatment of endometriosis. Womens Health (Lond). 2010;6:27-35.][Horie S, Harada T, Mitsunari M, et al. Progesterone and progestational compounds attenuate tumor necrosis factor alpha-induced interleukin-8 production via nuclear factor kappa B inactivation in endometriotic stromal cells. Fertil Steril. 2005;83:1530-5.][Katsuki Y, Takano Y, Futamura Y, et al. Effects of dienogest, a synthetic steroid, on experimental endometriosis in rats. Eur J Endocrinol. 1998;138:216-26.][Mita S, Shimizu Y, Notsu T, et al. Dienogest inhibits Toll-like receptor 4 expression induced by costimulation of lipopolysaccharide and high-mobility group box 1 in endometrial epithelial cells. Fertil Steril. 2011;96:1485-9.][Nirgianakis K, Grandi G, McKinnon B, et al. Dienogest mediates midkine suppression in endometriosis. Hum Reprod. 2016;31:1981-6.][Schindler AE. Dienogest in long-term treatment of endometriosis. Int J Womens Health. 2011;3:175-84.][Harada T, Momoeda M, Taketani Y, et al. Dienogest is as effective as intranasal buserelin acetate for the relief of pain symptoms associated with endometriosis–a randomized, double-blind, multicenter, controlled trial. Fertil Steril. 2009;91:675-81.][Kohler G, Faustmann TA, Gerlinger C, et al. A dose-ranging study to determine the efficacy and safety of 1, 2, and 4 mg of dienogest daily for endometriosis. Int J Gynaecol Obstet. 2010;108:21-5.][Strowitzki T, Faustmann T, Gerlinger C, Seitz C. Dienogest in the treatment of endometriosis-associated pelvic pain: A 12-week, randomized, double-blind, placebo-controlled study. Eur J Obstet Gynecol Reprod Biol. 2010;151:193-8.][Strowitzki T, Marr J, Gerlinger C, et al. Dienogest is as effective as leuprolide acetate in treating the painful symptoms of endometriosis: A 24-week, randomized, multicentre, open-label trial. Hum Reprod. 2010;25:633-41.][Strowitzki T, Marr J, Gerlinger C, et al. Detailed analysis of a randomized, multicenter, comparative trial of dienogest versus leuprolide acetate in endometriosis. Int J Gynaecol Obstet. 2012;117:22-33.][Оразов М.Р., Чайка А.В., Носенко Е.Н. Диеногест в лечении хронической тазовой боли при аденомиозе. Медико-социальные проблемы семьи. 2013;18(3). Режим доступа: http://www.mif-ua.com/archive/article_print/37185. Ссылка активна на 05.07.2021 [Orazov MR, Chaika AV, Nosenko EN. Dienogest v lechenii khronicheskoi tazovoi boli pri adenomioze. Mediko-sotsial'nye problemy sem'i. 2013;18(3). Available: http://www.mif-ua.com/archive/article_print/37185. Accessed: 05.07.2021(in Russian)].][Liu X, Guo SW. Dysmenorrhea: risk factors in women with endometriosis. Women's Health. 2008;4(4):399-411.][Strowitzki T, Faustmann A, Christoph G, Seitz C. Dienogest in the treatment of endometriosis-associated pelvic pain: a 12-week, randomized, double-blind, placebo-controlled study. Eur J Obstet Gynecol Reprod Biol. 2010;151:193-8.][Harada T, Momoeda M, Taketani Y, et al. Dienogest is as effective as intranasal buserelin acetate for the relief of pain symptoms associated with endometriosis – a randomized, double-blind, multicenter, controlled trial. Fertil Steril. 2009;91:675-81.][Katsuki Y, Takano Y, Futamura Y, et al. Effects of dienogest, a synthetic steroid, on experimental endometriosis in rats. Eur J Endocrinol. 1998;138:216-26.][Okada H, Nakajima T, Yoshimura T, et al. The inhibitory effect of dienogest, a synthetic steroid, on the growth of human endometrial stromal cells in vitro. Mol Hum Reprod. 2001;7:341-7.][Horie P, Harada T, Mitsunari M, et al. Progesterone and progestational compounds attenuate tumor necrosis factor alpha-induced interleukin-8 production via nuclear factor kappa B inactivation in endometriotic stromal cells. Fertil Steril. 2005;83:1530-5.][Chauvet P, Guiguet-Auclair C, Comptour A, et al. Feelings and expectations in endometriosis: Analysis of open comments from a cohort of endometriosis patients. J Gynecol Obstet Hum Reprod. 2018;47(7):281-7.][Shum LK, Bedaiwy MA, Allaire C, et al. Deep Dyspareunia and Sexual Quality of Life in Women With Endometriosis. Sex Med. 2018;6(3):224-33.][Yarmolinskaya M, Makarova I, Veremiova R, et al. A noninterventional study with dienogest 2 mg to assess the quality of life in patients with endometriosis (DIVA study). Presented at: 2nd Congress of the Society of Endometriosis and Uterine Disorders; May 12-14, 2016; Barcelona, Spain. Abstract 1576.][Iglesias-Rios L, Harlow SD, Reed BD. Depression and Posttraumatic Stress Disorder Among Women with Vulvodynia: Evidence from the Population-Based Woman to Woman Health Study. J Women's Health. 2015;24:557.]